Lonapegsomatropin
Sponsors
Ascendis Pharma Endocrinology Division A/S
Conditions
Adult Growth Hormone DeficiencyEndocrine System DiseasesGrowth Hormone DeficiencyHormone DeficiencyTurner SyndromeTurner Syndrome (TS)idiopathic short stature (ISS)short stature homeobox containing gene deficiency (SHOX-D)
Phase 2
Phase 3
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
CompletedNCT04615273
Start: 2020-12-03End: 2023-12-01Updated: 2026-07-07
A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
CompletedNCT05171855
Start: 2021-12-16End: 2024-12-23Updated: 2026-07-07
HighLiGHts - A Pivotal, Parallel-Arm, Phase 3, Open-Label, Active-controlled, Global, Multicenter, Randomized Basket Trial Investigating the Efficacy and Safety of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Children and Adolescents with Growth Failure or Short Stature due to Growth Hormone Sufficient Disorders – Turner Syndrome, SHOX Deficiency, Small for Gestational Age, and Idiopathic Short Stature
Not yet recruitingCTIS2025-523079-44-00
Target: 14Updated: 2026-02-27